EyePoint Pharmaceuticals - Laidlaw & Company

Project Description

Follow-On Offering
Common Stock
.

$115,000,000

Financial Advisor
February 2021

You are now leaving Laidlaw & Company

This link is provided as a service to you, and will take you to a third party site not affiliated with this site. We are not responsible for the content and do not guarantee the accuracy of any information or material contained therein Laidlaw & Company provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by Laidlaw & Company, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL

Project Description

Related

Project Details

You are now leaving Laidlaw & Company

Project Description

Related

Project Details

Share This Story, Choose Your Platform!

You are now leaving Laidlaw & Company